Several other research firms also recently weighed in on SHPG. HSBC downgraded shares of Shire PLC from a buy rating to a hold rating in a research report on Monday, September 26th. Shore Capital restated a buy rating on shares of Shire PLC in a research report on Tuesday, August 30th. Citigroup Inc. restated a buy rating on shares of Shire PLC in a research report on Tuesday, September 27th. Zacks Investment Research upgraded shares of Shire PLC from a hold rating to a buy rating and set a $208.00 price target for the company in a research report on Tuesday, July 5th. Finally, Jefferies Group restated a buy rating and set a $262.00 price target on shares of Shire PLC in a research report on Tuesday, September 20th. Five research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $232.75.
Shares of Shire PLC (NASDAQ:SHPG) opened at 194.37 on Monday. The firm has a 50-day moving average of $195.77 and a 200 day moving average of $186.79. Shire PLC has a 52 week low of $147.60 and a 52 week high of $231.32. The company has a market cap of $57.89 billion, a P/E ratio of 40.39 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.35. The business earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company’s revenue was up 55.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.63 earnings per share. Equities analysts expect that Shire PLC will post $12.92 EPS for the current fiscal year.
The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be issued a $0.139 dividend. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
Large investors have recently made changes to their positions in the stock. Macquarie Group Ltd. purchased a new stake in shares of Shire PLC during the second quarter worth $5,561,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Shire PLC by 157.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,645 shares of the biopharmaceutical company’s stock worth $1,591,000 after buying an additional 5,293 shares during the last quarter. Cowen Group Inc. purchased a new stake in shares of Shire PLC during the second quarter worth $920,000. Beacon Trust Co. purchased a new stake in shares of Shire PLC during the second quarter worth $2,643,000. Finally, IFP Advisors Inc raised its stake in shares of Shire PLC by 871.9% in the second quarter. IFP Advisors Inc now owns 2,702 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 2,424 shares during the last quarter. Institutional investors and hedge funds own 24.26% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.